Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transarterial bevacizumab infusion combined with TACE for TACE-refractory hepatocellular carcinoma
ChiCTR-OPC-15006859Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoint: overall survival. Started Aug 2015; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-OPC-15006859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15006859.